As of 2025-01-16, the EV/EBITDA ratio of Sorrento Therapeutics Inc (SRNE) is -0.21. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRNE's latest enterprise value is 72.73 mil USD. SRNE's TTM EBITDA according to its financial statements is -340.66 mil USD. Dividing these 2 quantities gives us the above SRNE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.0x - 17.8x | 16.2x |
| Forward P/E multiples | 15.1x - 24.3x | 19.0x |
| Fair Price | (4,833.60) - (5,707.11) | (5,653.31) |
| Upside | -1573024.7% - -1857278.4% | -1839770.0% |
| Date | EV/EBITDA |
| 2025-01-13 | -0.21 |
| 2025-01-10 | -0.21 |
| 2025-01-08 | -0.21 |
| 2025-01-07 | -0.21 |
| 2025-01-06 | -0.21 |
| 2025-01-03 | -0.21 |
| 2025-01-02 | -0.21 |
| 2024-12-31 | -0.21 |
| 2024-12-30 | -0.21 |
| 2024-12-27 | -0.21 |
| 2024-12-26 | -0.21 |
| 2024-12-24 | -0.21 |
| 2024-12-23 | -0.21 |
| 2024-12-20 | -0.21 |
| 2024-12-19 | -0.21 |
| 2024-12-18 | -0.21 |
| 2024-12-17 | -0.21 |
| 2024-12-16 | -0.21 |
| 2024-12-13 | -0.21 |
| 2024-12-12 | -0.21 |
| 2024-12-11 | -0.21 |
| 2024-12-10 | -0.21 |
| 2024-12-09 | -0.21 |
| 2024-12-06 | -0.21 |
| 2024-12-05 | -0.21 |
| 2024-12-04 | -0.21 |
| 2024-12-03 | -0.21 |
| 2024-12-02 | -0.21 |
| 2024-11-29 | -0.21 |
| 2024-11-27 | -0.21 |
| 2024-11-26 | -0.21 |
| 2024-11-25 | -0.21 |
| 2024-11-22 | -0.21 |
| 2024-11-21 | -0.21 |
| 2024-11-20 | -0.21 |
| 2024-11-19 | -0.21 |
| 2024-11-18 | -0.21 |
| 2024-11-15 | -0.21 |
| 2024-11-14 | -0.21 |
| 2024-11-13 | -0.21 |
| 2024-11-12 | -0.21 |
| 2024-11-11 | -0.21 |
| 2024-11-08 | -0.21 |
| 2024-11-07 | -0.21 |
| 2024-11-06 | -0.21 |
| 2024-11-05 | -0.21 |
| 2024-11-04 | -0.21 |
| 2024-11-01 | -0.21 |
| 2024-10-31 | -0.21 |
| 2024-10-30 | -0.21 |